Morling Financial Advisors, LLC Abb Vie Inc. Transaction History

Morling Financial Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$159.82 - $182.1 $40,274 - $45,889	-252 Reduced 15.48%	1,376 $250,000
Q4 2023 Feb 02, 2024	BUY	$137.6 - $154.97 $1,238 - $1,394	9 Added 0.56%	1,628 $252,000
Q3 2023 Nov 08, 2023	SELL	$133.59 - $154.65 $7,213 - $8,351	-54 Reduced 3.23%	1,619 $241,000
Q2 2023 Jul 28, 2023	SELL	$132.51 - $164.9 $2,915 - $3,627	-22 Reduced 1.3%	1,673 $225,000
Q1 2023 May 02, 2023	SELL	$144.61 - $166.54 $21,546 - $24,814	-149 Reduced 8.08%	1,695 $270,000
Q4 2022 Feb 03, 2023	SELL	$138.31 - $165.87 $43,291 - $51,917	-313 Reduced 14.51%	1,844 $298,000
Q3 2022 Nov 01, 2022	BUY	$134.21 - $153.93 $671 - $769	5 Added 0.23%	2,157 $290,000
Q2 2022 Aug 01, 2022	SELL	$137.62 - $174.96 $14,312 - $18,195	-104 Reduced 4.61%	2,152 $330,000
Q1 2022 May 06, 2022	BUY	$131.98 - $163.75 $28,243 - $35,042	214 Added 10.48%	2,256 $366,000
Q4 2021 Feb 04, 2022	BUY	$107.43 - $135.93 $219,372 - $277,569	2,042 New	2,042 $277,000

3,870

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Morling Financial Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Morling Financial Advisors, LLC with notifications on news.